Try

NEVRO CORP.

NVROUnited States

39 filed reports · 413 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

FigureLatest fiscal yearLatest quarter
Revenue$409MFY2024 · to Dec 31, 2024−3.9% from $425M10-K$96.9MQ3 FY2024 · to Sep 30, 2024−6.7% from $104M10-Q
Net income-$113MFY2024 · to Dec 31, 2024a year earlier: -$92.2M10-K-$15.3MQ3 FY2024 · to Sep 30, 2024a year earlier: -$23.5M10-Q
Operating income-$126MFY2024 · to Dec 31, 2024a year earlier: -$99.3M10-K-$13.9MQ3 FY2024 · to Sep 30, 2024a year earlier: -$25.6M10-Q

Filed reports

39 reports · Jun 2015 to Dec 2024

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR293,777Jun 2015 to Sep 2024
Annual · 10-KSEC EDGAR104,258Dec 2015 to Dec 2024

Documents

PeriodTypePeriod endPublishedFactsSource
FY202410-KDec 31, 2024Mar 4, 20251,021Open
FY2024 Q310-QSep 30, 2024Nov 12, 2024256Open
FY2024 Q210-QJun 30, 2024Aug 6, 2024211Open
FY2024 Q110-QMar 31, 2024May 7, 2024210Open
FY202310-KDec 31, 2023Feb 23, 2024431Open
FY2023 Q310-QSep 30, 2023Nov 1, 2023162Open
FY2023 Q210-QJun 30, 2023Aug 1, 2023128Open
FY2023 Q110-QMar 31, 2023Apr 26, 2023132Open
FY202210-KDec 31, 2022Feb 21, 2023367Open
FY2022 Q310-QSep 30, 2022Nov 2, 2022154Open
FY2022 Q210-QJun 30, 2022Aug 3, 2022121Open
FY2022 Q110-QMar 31, 2022May 4, 2022124Open

Financial data

413 concepts · 8,035 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial399 concepts · 7,913 facts · Dec 2013 to Dec 2024

  • Cash and cash equivalents at carrying value56 · Dec 2013 to Dec 2024
  • Comprehensive income net of tax56 · Dec 2013 to Dec 2024
  • Depreciation depletion and amortization56 · Dec 2013 to Dec 2024
  • Foreign currency transaction gain loss realized56 · Dec 2013 to Dec 2024
  • Gross profit (US GAAP)56 · Dec 2013 to Dec 2024
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest56 · Dec 2013 to Dec 2024
  • Income tax expense benefit56 · Dec 2013 to Dec 2024
  • Investment income interest56 · Dec 2013 to Dec 2024
  • Net income loss56 · Dec 2013 to Dec 2024
  • Operating expenses (US GAAP)56 · Dec 2013 to Dec 2024
  • Operating income loss56 · Dec 2013 to Dec 2024
  • Other comprehensive income availableforsale securities adjustment net of tax portion attributable to parent56 · Dec 2013 to Dec 2024
  • Other comprehensive income loss net of tax portion attributable to parent56 · Dec 2013 to Dec 2024
  • Other nonoperating income expense56 · Dec 2013 to Dec 2024
  • Research and development expense56 · Dec 2013 to Dec 2024
  • Revenue56 · Dec 2013 to Dec 2024
  • Selling general and administrative expense56 · Dec 2013 to Dec 2024
  • Foreign currency transaction gain loss unrealized55 · Mar 2014 to Dec 2024
  • Accretion amortization of discounts and premiums investments54 · Dec 2013 to Dec 2024
  • Antidilutive securities excluded from computation of earnings per share amount54 · Dec 2013 to Dec 2024
  • Increase decrease in accounts payable54 · Dec 2013 to Dec 2024
  • Increase decrease in accounts receivable54 · Dec 2013 to Dec 2024
  • Increase decrease in inventories54 · Dec 2013 to Dec 2024
  • Increase decrease in other noncurrent liabilities54 · Dec 2013 to Dec 2024

Geography1 concept · 69 facts · Sep 2015 to Dec 2024

  • Revenue69 · Sep 2015 to Dec 2024

Segment11 concepts · 33 facts · Dec 2022 to Dec 2024

  • Cost of revenue (US GAAP)3 · Dec 2022 to Dec 2024
  • General and administrative expense (US GAAP)3 · Dec 2022 to Dec 2024
  • Income tax expense benefit3 · Dec 2022 to Dec 2024
  • Marketing expense3 · Dec 2022 to Dec 2024
  • Net income loss3 · Dec 2022 to Dec 2024
  • Nonoperating income expense3 · Dec 2022 to Dec 2024
  • Other operating income expense net3 · Dec 2022 to Dec 2024
  • Regulatory And Clinical Expense3 · Dec 2022 to Dec 2024
  • Research and development expense3 · Dec 2022 to Dec 2024
  • Revenue3 · Dec 2022 to Dec 2024
  • Selling expense3 · Dec 2022 to Dec 2024

Product2 concepts · 20 facts · Sep 2021 to Dec 2023

  • Revenue12 · Sep 2021 to Dec 2023
  • Percentage Of P D N Permanent Implant Procedures8 · Mar 2022 to Dec 2023

Segments

122 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement geographicalsrt:StatementGeographicalAxis2 members · 64 facts

  • International [Member]32 · Mar 2017 to Dec 2024
  • United States [Member]32 · Mar 2017 to Dec 2024

Statement business segments1 member · 33 facts

  • Reportable Segment33 · Dec 2022 to Dec 2024

Product or service1 member · 20 facts

  • Painful Diabetic Neuropathy [Member]20 · Sep 2021 to Dec 2023

Statement geographicalus-gaap:StatementGeographicalAxis2 members · 5 facts

  • United States [Member]3 · Sep 2015 to Mar 2018
  • International [Member]2 · Mar 2017 to Mar 2018

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of NEVRO CORP. (NVRO) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.